Johnson & Johnson says it’s using artificial intelligence to accelerate multiple stages of drug development. The firm reports that AI has halved the time to identify promising new drug candidates. It also says AI is streamlining manufacturing and significantly reducing the time required to prepare regulatory documentation, potentially shortening the path from concept to approval.
Eli Lilly plans to acquire Ajax Therapeutics for up to $2.3 billion to develop a potential new oral treatment for myelofibrosis, a rare blood cancer. The company expects key clinical data in 2026 and intends to rapidly advance the program into larger trials, aiming to add another targeted option for patients and specialists.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
